

Special Issue

Chronic Lymphocytic Leukemia: From Genetics to Therapy

Message from the Guest Editor

In recent years, targeted therapies have generated spectacular outcomes in clinical practice and have changed the treatment for patients with Chronic Lymphocytic Leukemia (CLL). Relevant insights are being unraveled from a biologic point of view, including the potential relevance of complex karyotype, novel genetic and molecular techniques, and the validation of those in the era of novel drugs. The current challenge for CLL treatment may include the lack of optimal evidence to recommend options or sequencing them in any given scenario. The purpose of this Special Issue is to understand the current pros and cons of different treatment options and explore new opportunities for effective anticancer therapies. This Special Issue welcomes reviews, as well as original research articles.

Guest Editor

Dr. Javier Loscertales-Pueyo

Hematology Department, Hospital Universitario de la Princesa,
Universidad Autonoma Madrid, 28006 Madrid, Spain

Deadline for manuscript submissions

28 February 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/237119

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)